Lidokain GALENpharma (Lidocaine)

What Is Lidokain GALENpharma and What Is It Used For?

Lidocaine, the active ingredient in Lidokain GALENpharma, is one of the most commonly used local anesthetics worldwide. First synthesized in 1943 by Swedish chemist Nils Löfgren, lidocaine represented a significant advancement over earlier local anesthetics such as procaine (Novocain) due to its improved stability, faster onset, and lower incidence of allergic reactions. Today, it remains a cornerstone of local anesthesia practice and is included on the World Health Organization's List of Essential Medicines.

As an amide-type local anesthetic, lidocaine works by reversibly blocking voltage-gated sodium channels in neuronal cell membranes. When applied or injected near nerve fibers, it prevents the generation and propagation of action potentials, thereby blocking the transmission of pain signals from the peripheral nervous system to the brain. This mechanism provides temporary and localized numbness without causing loss of consciousness, making it ideal for a wide range of medical procedures.

Lidokain GALENpharma is manufactured by GALENpharma and is available in several formulations designed for different clinical applications. Injectable solutions are used for infiltration anesthesia, peripheral nerve blocks, and epidural anesthesia during surgical procedures. Topical formulations (creams, gels, and sprays) are applied directly to the skin or mucous membranes to numb the area before minor procedures such as wound suturing, venipuncture, or catheter insertion. Medicated plasters provide sustained release of lidocaine for the management of localized neuropathic pain conditions.

Common Clinical Uses

Lidocaine has an exceptionally broad range of clinical applications, reflecting its versatility and favorable safety profile. In dental practice, it is the most frequently used local anesthetic for tooth extractions, fillings, root canal treatments, and other procedures requiring localized numbness of the oral cavity. In surgery, lidocaine is used for local infiltration anesthesia during minor surgical procedures, regional nerve blocks for more extensive operations, and epidural or spinal anesthesia for lower body procedures.

Beyond its primary role as a local anesthetic, lidocaine is also used in dermatology for numbing the skin before biopsies, excisions, or laser treatments. In emergency medicine, it serves as a Class Ib antiarrhythmic agent for the acute management of certain ventricular arrhythmias, though this use has declined with the availability of newer alternatives. Topical lidocaine preparations are widely used for the relief of post-herpetic neuralgia (nerve pain following shingles), minor burns and skin irritations, and pain associated with hemorrhoids and other anorectal conditions.

What Should You Know Before Taking Lidokain GALENpharma?

While lidocaine is generally considered safe when administered at appropriate doses by trained healthcare professionals, there are several important considerations that patients and clinicians should be aware of before its use. Understanding the contraindications, warnings, and potential interactions associated with lidocaine is essential for minimizing risks and ensuring optimal outcomes.

Contraindications

Lidocaine should not be used in patients with a known hypersensitivity to lidocaine or any other amide-type local anesthetics (such as bupivacaine, mepivacaine, prilocaine, or ropivacaine). Cross-reactivity between amide-type anesthetics is rare but possible, and patients who have experienced a true allergic reaction to one amide-type agent should be carefully evaluated before receiving another. Importantly, cross-reactivity between amide-type and ester-type local anesthetics (such as procaine or tetracaine) is extremely rare, so ester-type agents may serve as alternatives for patients with confirmed amide allergy.

Lidocaine injection is also contraindicated in patients with severe sinoatrial, atrioventricular, or intraventricular heart block (unless a functioning pacemaker is in place), as the drug's sodium channel-blocking properties may further impair cardiac conduction. Additionally, lidocaine should not be injected into inflamed or infected tissues, as the acidic pH of such tissues reduces the effectiveness of the anesthetic, and the increased vascularity may promote rapid systemic absorption.

Warnings and Precautions

Hepatic impairment is a significant concern with lidocaine use, as the drug is primarily metabolized by the liver via the cytochrome P450 system (mainly CYP1A2 and CYP3A4). Patients with liver disease, including cirrhosis and hepatitis, may have significantly reduced clearance of lidocaine, leading to elevated plasma levels and an increased risk of systemic toxicity. Dose reductions are recommended for these patients, and careful monitoring is advised.

Elderly patients may also require dose adjustments, as age-related decreases in liver blood flow and hepatic enzyme activity can slow lidocaine metabolism. Additionally, elderly patients may have increased sensitivity to the cardiovascular and central nervous system effects of local anesthetics. The lowest effective dose should always be used, and aspiration should be performed before injection to avoid inadvertent intravascular administration.

Patients with severe cardiac disease, including heart failure and cardiogenic shock, should receive lidocaine with extreme caution. The drug's negative inotropic effects and its ability to slow cardiac conduction can exacerbate these conditions. Similarly, patients with epilepsy may be at increased risk of seizures from systemic lidocaine, as the drug can lower the seizure threshold at toxic concentrations.

Pregnancy and Breastfeeding

Lidocaine crosses the placental barrier by passive diffusion, and fetal plasma concentrations can reach 60–70% of maternal levels. However, extensive clinical experience and available evidence suggest that lidocaine, when used at recommended doses, does not pose a significant risk to the developing fetus. The U.S. FDA previously classified lidocaine as Pregnancy Category B, indicating that animal studies have not demonstrated fetal risk and there are no adequate controlled studies in humans, but available data do not suggest harm.

Lidocaine is widely used during pregnancy for dental procedures and episiotomy repair, and it is a component of many epidural anesthetic regimens used during labor and delivery. The consensus among major professional organizations, including the American College of Obstetricians and Gynecologists (ACOG) and the European Medicines Agency (EMA), is that lidocaine can be used during pregnancy when the clinical benefit justifies the potential risk, using the minimum effective dose.

Lidocaine is excreted in breast milk in small amounts, with a milk-to-plasma ratio of approximately 0.4. Given the low oral bioavailability of lidocaine in infants and the small quantities present in breast milk, the drug is generally considered compatible with breastfeeding when used at standard therapeutic doses. The American Academy of Pediatrics has classified lidocaine as compatible with breastfeeding.

How Does Lidokain GALENpharma Interact with Other Drugs?

Drug interactions with lidocaine are clinically significant because they can alter the drug's pharmacokinetics (how the body processes the drug) or pharmacodynamics (how the drug affects the body). Understanding these interactions is particularly important when lidocaine is used systemically (e.g., intravenous infusion for arrhythmias) or when large doses are administered for regional anesthesia, as these scenarios produce the highest systemic drug levels.

Major Interactions

The most clinically significant interactions involve drugs that inhibit the hepatic metabolism of lidocaine, leading to elevated plasma concentrations and an increased risk of toxicity. Cimetidine, a histamine H2-receptor antagonist, is a potent inhibitor of CYP1A2 and CYP3A4 and can significantly increase lidocaine levels. Patients receiving concurrent cimetidine therapy should have their lidocaine dose reduced and be monitored closely for signs of toxicity. Other proton pump inhibitors and H2-receptor antagonists do not significantly affect lidocaine metabolism.

Beta-adrenergic blocking agents, particularly propranolol, can reduce hepatic blood flow and thereby decrease lidocaine clearance by up to 40%. This interaction is clinically relevant when lidocaine is administered systemically and may necessitate dose adjustments. Additionally, beta-blockers can potentiate the negative inotropic and dromotropic effects of lidocaine on the heart, increasing the risk of bradycardia and hypotension.

Concurrent use of lidocaine with other local anesthetics or structurally related drugs (such as Class Ib antiarrhythmics like mexiletine or tocainide) can produce additive or synergistic toxic effects. The total dose of all local anesthetics administered should be considered when calculating safe dosing limits to prevent systemic toxicity.

Minor Interactions

Certain antimicrobial agents, including erythromycin, ciprofloxacin, and fluconazole, can inhibit CYP3A4 or CYP1A2 and may modestly increase lidocaine plasma levels. While these interactions are generally less clinically significant than those with cimetidine or beta-blockers, they should be considered when lidocaine is used at higher doses or in patients with other risk factors for toxicity.

Phenytoin and other hepatic enzyme inducers (such as rifampicin and carbamazepine) can increase the metabolism of lidocaine, potentially reducing its efficacy. Dose adjustments may be necessary in patients receiving chronic therapy with these agents. Conversely, substances that reduce hepatic blood flow, including general anesthetics and certain vasopressors, may decrease lidocaine clearance.

What Is the Correct Dosage of Lidokain GALENpharma?

The appropriate dosage of lidocaine varies significantly depending on the route of administration, the specific clinical indication, the patient's body weight, age, and overall health status. Dosing must be individualized based on these factors, with the goal of using the minimum dose necessary to achieve adequate anesthesia or pain relief while minimizing the risk of systemic toxicity.

Adults

For injectable lidocaine used in local infiltration anesthesia, the standard concentration ranges from 0.5% to 2% (5–20 mg/mL). The volume administered depends on the size of the area to be anesthetized and the specific procedure. For lidocaine without epinephrine, the maximum recommended dose is 4.5 mg/kg body weight, not exceeding 300 mg as a single dose. When combined with epinephrine, the maximum dose increases to 7 mg/kg, not exceeding 500 mg, due to the slower systemic absorption achieved by the vasoconstrictive effect of epinephrine.

For topical application, lidocaine is available in concentrations of 2% to 5%. Creams and gels are typically applied to the affected area in a thin layer, with the amount adjusted to the size of the treatment area. For medicated plasters (5% lidocaine), the standard recommendation is to apply up to three plasters simultaneously for a maximum of 12 hours per 24-hour period. The plasters should be applied to intact, dry, non-irritated skin over the most painful area.

Children

In pediatric patients, lidocaine dosing is strictly weight-based to minimize the risk of systemic toxicity. Children have a proportionally larger volume of distribution and may metabolize lidocaine differently than adults. The maximum recommended dose for children is 4.5 mg/kg without epinephrine and 7 mg/kg with epinephrine, similar to adult limits on a per-kilogram basis. However, the total absolute dose must be carefully calculated based on the child's exact body weight.

For topical application in children, lidocaine cream (e.g., EMLA, which contains lidocaine and prilocaine) is widely used before venipuncture, vaccination, and minor dermatological procedures. Application time and area should be limited according to the child's age and weight, as excessive application can lead to significant systemic absorption through the thinner skin of young children.

Elderly

Elderly patients (generally defined as over 65 years of age) often require reduced doses of lidocaine due to age-related changes in pharmacokinetics. Decreased hepatic blood flow, reduced liver mass, and declining enzyme activity can slow lidocaine metabolism, leading to prolonged drug action and increased plasma levels. Additionally, elderly patients may have increased sensitivity to the central nervous system and cardiovascular effects of lidocaine. A dose reduction of 25–50% from the standard adult dose is generally recommended, and the drug should be administered slowly with careful monitoring.

Missed Dose

Lidocaine is typically administered as a single dose for a specific procedure or applied as needed for pain relief, rather than taken on a regular schedule. Therefore, the concept of a "missed dose" is generally not applicable. For medicated plasters used for chronic pain management, if you forget to apply a plaster at the usual time, apply it as soon as you remember, but do not apply additional plasters to make up for the missed one. Maintain the 12-hours-on / 12-hours-off cycle.

Overdose

Lidocaine overdose can result in Local Anesthetic Systemic Toxicity (LAST), which is a medical emergency. Early symptoms of LAST include perioral numbness and tingling, a metallic taste in the mouth, lightheadedness, tinnitus (ringing in the ears), and visual disturbances. As toxicity progresses, patients may develop muscle twitching, tremors, and generalized tonic-clonic seizures. In severe cases, cardiovascular toxicity occurs, manifested by hypotension, bradycardia, ventricular arrhythmias, and ultimately cardiac arrest.

The management of LAST follows established protocols published by the American Society of Regional Anesthesia and Pain Medicine (ASRA). The primary treatment involves immediate cessation of lidocaine administration, airway management with 100% oxygen, seizure control with benzodiazepines, and intravenous lipid emulsion therapy (20% Intralipid). Lipid emulsion acts as a "lipid sink," binding free lidocaine molecules in the plasma and sequestering them away from cardiac and neural tissue. Early initiation of lipid rescue therapy has been shown to significantly improve outcomes in LAST.

What Are the Side Effects of Lidokain GALENpharma?

Like all medications, lidocaine can cause side effects, although not everyone experiences them. The nature and severity of side effects depend largely on the route of administration, the dose used, and individual patient factors. Topical application generally carries a lower risk of systemic side effects compared to injectable formulations, as systemic absorption is more limited. Understanding the spectrum of potential side effects helps patients and healthcare providers make informed decisions about the use of this medication.

Side effects can be broadly categorized into local reactions (occurring at the site of application or injection) and systemic reactions (resulting from absorption of lidocaine into the bloodstream). Local reactions are far more common and are usually mild and self-limiting. Systemic reactions are dose-dependent and are more likely to occur when maximum recommended doses are exceeded or when the drug is inadvertently injected into a blood vessel.

The following classification of side effects is based on data from clinical trials, post-marketing surveillance, and international pharmacovigilance databases. Frequencies are categorized according to the standard MedDRA convention used by the European Medicines Agency (EMA) and other regulatory bodies.

Most local side effects resolve spontaneously within hours to days after the procedure. Application site reactions from topical formulations, such as erythema (redness), edema (swelling), and blanching (whitening of the skin), are usually transient and result from the pharmacological action of the drug rather than an allergic reaction. These effects typically do not require treatment and resolve once the product is removed.

True allergic reactions to lidocaine and other amide-type local anesthetics are exceedingly rare, occurring in less than 1% of all adverse reactions. Many reactions previously attributed to "lidocaine allergy" are actually caused by preservatives (such as methylparaben) or vasoconstrictors (epinephrine) in the formulation, by vasovagal syncope (fainting), or by anxiety-related symptoms. When a genuine allergy is suspected, referral to an allergist for skin testing is recommended before labeling a patient as allergic to amide-type anesthetics.

How Should You Store Lidokain GALENpharma?

Proper storage of lidocaine products is essential to maintain their efficacy and safety throughout the shelf life. Different formulations may have specific storage requirements, and it is important to follow the instructions provided on the product packaging and patient information leaflet.

Injectable lidocaine solutions should be stored at controlled room temperature, typically between 15°C and 25°C (59°F to 77°F). They should be protected from light and should not be frozen, as freezing can alter the chemical stability and physical properties of the solution. Inspect injectable solutions visually before use; do not use if the solution is discolored, cloudy, or contains particulate matter. Single-use vials and ampoules should be discarded after opening, even if some drug remains, as they typically do not contain preservatives.

Topical lidocaine products (creams, gels, and ointments) should also be stored at room temperature and protected from direct sunlight and excessive heat. Tubes should be tightly closed after each use to prevent contamination and drying out. Medicated plasters should be stored in their original sealed sachets until immediately before use, as exposure to air can reduce their adhesive properties and drug-release characteristics.

All lidocaine products should be kept out of the reach and sight of children and should not be used after the expiration date stated on the packaging. Expired medications should be disposed of according to local regulations — do not flush them down the toilet or throw them in household waste unless specifically instructed to do so. Many pharmacies and healthcare facilities accept expired or unused medications for safe disposal.

What Does Lidokain GALENpharma Contain?

Lidokain GALENpharma contains lidocaine as its active pharmaceutical ingredient, typically in the form of lidocaine hydrochloride monohydrate. Lidocaine hydrochloride is a white crystalline powder that is freely soluble in water, making it suitable for both injectable and topical formulations. The exact composition varies depending on the specific product formulation.

Injectable Solutions

Injectable lidocaine solutions contain lidocaine hydrochloride dissolved in water for injections. The solution is adjusted to a pH of approximately 5.0–7.0 using sodium hydroxide or hydrochloric acid. Sodium chloride may be added to achieve isotonicity. Some multi-dose vials may contain methylparaben or other preservatives, while single-dose vials and ampoules are preservative-free. Formulations containing epinephrine also include sodium metabisulfite as an antioxidant to prevent degradation of the epinephrine.

Topical Formulations

Topical lidocaine products contain lidocaine (either as the free base or the hydrochloride salt) in a cream, gel, or ointment base. Common excipients in topical formulations include propylene glycol (humectant and penetration enhancer), cetyl alcohol and stearyl alcohol (emulsion stabilizers), mineral oil or white petrolatum (emollient base), methylparaben and propylparaben (preservatives), and purified water. Patients with known sensitivities to any of these excipients should review the full ingredient list before use.

Medicated Plasters

Lidocaine medicated plasters consist of an adhesive material containing 5% lidocaine applied to a non-woven polyester backing. The adhesive layer typically contains dihydroxyaluminium aminoacetate, disodium edetate, gelatin, glycerol, kaolin, d-sorbitol, polyacrylic acid, sodium polyacrylate, carmellose sodium, polyvinyl alcohol, and purified water. The plaster is designed to provide controlled, sustained release of lidocaine through intact skin over a 12-hour application period.